Treatment with celecoxib significantly improved the insulin sensitivity and reduced the glucose AUC by about 31% in the T2DM-NASH-Cele group (Table 2; Fig. 1C). This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.